Ernexa Therapeutics Inc
Research Ernexa Therapeutics Inc (ERNA) on Bullrun: market cap USD 5.77M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerERNA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.77M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 5.51M
- Free cash flow-USD 2.27M
Valuation Snapshot
latest market cap is USD 5.77M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 14.08M | -USD 7.05M | n/a | -2.24 | USD 1.88M | USD 490.00K | USD 2.40M |
| FY2024 | USD 582.00K | -USD 44.54M | -USD 16.21M | 83.5% | -48.96 | USD 1.73M | USD 684.00K | USD 1.70M |
| FY2023 | USD 68.00K | -USD 21.67M | -USD 20.43M | -247.1% | -4.08 | USD 7.58M | USD 41.84M | USD 2.23M |
| FY2022 | USD 0 | -USD 24.58M | -USD 21.27M | n/a | -8.06 | USD 11.45M | USD 2.82M | USD 12.11M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.77M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 9.43M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 14.90M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 9.72M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 16.54M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 215.80M | n/a | n/a | n/a |
About Ernexa Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ernexa Therapeutics Inc's market cap?
Ernexa Therapeutics Inc's market capitalization is USD 5.77M.
What does Ernexa Therapeutics Inc do?
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc.